



A general approach to the galanthamine ring system

Philip J. Parsons,^{a,*} Mark D. Charles,^a Darren M. Harvey,^a L. Ravi Sumoreeah,^a Adrian Shell,^a
Grant Spoor,^a Adrian L. Gill^b and Steve Smith^c

^aSussex University, CPES, Falmer, Brighton, East Sussex BN1 9QJ, UK

^bRoche Discovery Welwyn, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, UK

^cGlaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK


Received 13 October 2000; accepted 17 January 2001

Abstract—An approach to the galanthamine ring system is reported, which utilises an intramolecular Heck reaction to establish the benzofuran ring system present in both galanthamine and morphine. © 2001 Elsevier Science Ltd. All rights reserved.

Galanthamine (**1**) is an alkaloid with a structure related to morphine (**2**). It is isolated from the Caucasian snow-drop, *Galanthus woronowii*¹ as well as the bulbs of *Amaryllidaceae*. Galanthamine has been shown to exhibit potent acetylcholinesterase inhibitory activity² and as such is a primary candidate in the management of Alzheimer's disease. A recent publication by Fels et al.,³ has prompted us to comment upon our research in this area.

Our approach to both galanthamine and morphine relies on an efficient route to alkenes **6a** and **6b** which were synthesised using Heck methodology (Scheme 1).


We employed a similar synthetic scheme to Fels et al.,³ utilising a Mitsunobu⁴ coupling of phenol **3**;⁵ however, we found that using tributylphosphine and the morpholine derivative of DEAD made purification easier. In our case, intramolecular Heck⁶ cyclisation proceeded in lower yields with formation of the isomeric alkene (**7**) from palladium(0) mediated isomerisation when potassium carbonate is used as a base. The use of silver(I) salts in Heck reactions prevents double bond isomerisation as described by Overman et al.⁷ Indeed, in our case, changing the base to silver(I) carbonate gave exclusively alkene **6** in 75% yield with no evidence of isomeric alkene **7**.



Scheme 1. Reagents: (i) azodicarboxylic dimorpholide, Bu₃P, THF, 65%. (ii) Pd(OAc)₂, Ag₂CO₃, ethylenebis(diphenylphosphine), DMF, reflux 2 hours, 75%.

Keywords: galanthamine; morphine; Mitsunobu; intramolecular Heck; allylic oxidation.

* Corresponding author.



Our allylic alcohol **4** was synthesised by a reliable and highly efficient route utilising Birch⁸ reduction chemistry (Scheme 2). Birch reduction of methyl 2-methoxybenzoate under standard conditions gave the cyclohexadiene (**8**) in 83% yield. Deprotonation with LDA, and subsequent quenching with the bromoacetamide (**9**),^{9,10} cleanly produced **10** in almost quantitative yield. Saponification of the ester (**10**) and hydrolysis with concentrated hydrochloric acid generated the β -keto acid, which spontaneously decarboxylated to furnish isomeric cyclohexenes **11** and **12**. These were converted into the 2-ene isomer (**11**) by heating in THF and 1 M HCl in an overall yield of 92%. The enone (**11**) was reduced with sodium borohydride, interestingly with no 1,4 reduction occurring, to yield allylic alcohol **4**.


In order to obtain the galanthamine ring system (**14**) the aldehyde (**6a**) was condensed with methylamine, and subsequent sodium borohydride reduction afforded the secondary amine (**13**). The hydrochloride salt of this

amine was heated under high vacuum to produce the galanthamine ring system (**14**) in 92% yield (Scheme 3).¹¹ This is the same intermediate that Fels and co-workers reported and are intending to manipulate at the allylic position. However, we wish to report our findings in this area, as we have found allylic oxidation of **14** to be problematic as shown in Table 1.


In addition we have also attempted to introduce the desired functionality via various other methods. These include using NBS to produce an allylic bromide which could be manipulated using the procedure of Lallemand et al.¹² However, only a complex mixture was obtained. The use of molecular bromine as an alternative resulted in bromination of the aromatic ring. Epoxidation of **14** and base mediated ring opening was also attempted. Although the epoxide could be produced from 1,1,1-trifluoromethylmethyldioxirane,¹³ ring opening could not be effected with a variety of bases.

We are currently investigating a synthetic route to morphine utilising intermediate **6b** in a [3+2] nitrile oxide cycloaddition. The nitroalkane (**6b**) can be smoothly converted with phenylisocyanate in DCM and catalytic triethylamine to the isoxazoline (**17**) in 80% yield.

In summary we have developed a route to the galanthamine ring system by a conceptually similar route to that of Fels et al., and we have shown that manipulation of the allylic position is a far from trivial matter. We are also continuing our research efforts toward






Scheme 2. Reagents: (i) K, liq. NH_3 , THF, *t*-BuOH; NH_4Cl , 83%. (ii) LDA, THF, **9**, 95%. (iii) NaOH, H_2O ; conc. HCl. (iv) 1 M HCl, THF, 92%. (v) NaBH_4 , MeOH, 75%.



Scheme 3. Reagents: (i) MeNH_2 , EtOH, rt; NaBH_4 , MeOH, 90%. (ii) HCl, MeOH; vacuum, 120°C, 92%.

Table 1. Results from attempted allylic oxidation of **14**

Reagents and conditions	Starting material (%)	Cleaved lactam 15 (%)	Imide 16 (%)	Complex mixture
SeO ₂ , EtOH, heat	100	—	—	—
SeO ₂ , <i>tert</i> -BuOH, 150°C	100	—	—	—
SeO ₂ , HCO ₂ H, dioxane	60	—	—	—
Cr(CO) ₆ , TBHP, MeCN	—	90	—	—
MnO ₂ , DCM, rt	—	20	70	—
Pd(OAc) ₂ , MnO ₂ , AcOH, heat	—	70	—	—
CuI, TBHP, benzene, heat	—	80	—	—
CuBr, TBHP, benzene, heat	—	70	—	—
Pb(OAc) ₄ , AcOH, rt	90	—	—	—
CrO ₃ , <i>t</i> -BuOH, rt	—	60	—	—
CrO ₃ , DMP, –20°C	—	40	50	—
PDC, TBHP, benzene, rt	—	—	—	✓
[Rh ₃ O(OAc) ₆ CH ₂ O]OAc, TBHP, AcOH,	100	—	—	—



galanthamine, by utilising an alternative procedure for introduction of the oxygen functionality. In addition research toward morphine is continuing and will be reported at a later date.

Acknowledgements

We thank Dr. Bonnie Davis for helping to support this work and to Professor Madeleine Joullié for her continued interest. We also thank Roche Discovery Welwyn and Glaxo Wellcome for financial support.

References

- Proskurnina, N. F.; Yakovleva, A. P. *J. Gen. Chem.* **1952**, 22, 1899.
- Thomsen, T.; Kewitz, H. *Life Sci.* **1990**, 46, 1553.
- Pilger, C.; Westermann, B.; Flörke, U.; Fels, G. *Synlett* **2000**, 1163.
- Mitsunobu, O. *Synthesis* **1981**, 1.
- Markovich, K. M.; Tantishaiyakul, U.; Hamada, A.; Miller, D. D.; Romstedt, K. J.; Shams, G.; Shin, Y.; Fraundorfer, P. F.; Doyle, K.; Feller, D. R. *J. Med. Chem.* **1992**, 35, 466.
- Heck, R. F. *J. Am. Chem. Soc.* **1968**, 90, 5518.
- Abelman, M. M.; Oh, T.; Overman, L. E. *J. Org. Chem.* **1987**, 52, 4130.
- Birch, A. J. *J. Chem. Soc.* **1950**, 1551.
- Hook, J. M.; Mander, L. N.; Woolias, M. *Tetrahedron Lett.* **1982**, 23, 1095.
- Bartlett, P. A.; Carruthers, N. I.; Winter, B. M.; Long, K. *P. J. Org. Chem.* **1982**, 47, 1284.
- Harvey, D. M. PhD Thesis, University of Sussex, 1999.
- Bouchard, H.; Renard, P. Y.; Lallemand, J. Y. *Tetrahedron Lett.* **1991**, 32, 5953.
- Yang, D.; Wong, M. K.; Yip, C. *J. Org. Chem.* **1995**, 60, 3887.